Comparison of the acute renal and peripheral vascular responses to frusemide and bumetanide at low and high dose

British Journal of Clinical Pharmacology
A P PassmoreG D Johnston


1. The effects of equipotent doses of frusemide (10 mg and 100 mg) and bumetanide (250 micrograms and 2.5 mg) upon renal and peripheral vascular responses, urinary prostaglandin excretion, plasma renin activity, angiotensin II and noradrenaline were compared in nine healthy volunteers. 2. Frusemide (10 mg and 100 mg) and bumetanide (2.5 mg) increased renal blood flow acutely compared with placebo but bumetanide (250 micrograms) had no effect. The changes in peripheral vascular responses were not significantly different from placebo. 3. Urinary prostaglandin metabolite excretion was acutely increased by all treatments, with no inter-treatment difference. Plasma renin activity was increased acutely by both doses of frusemide and by bumetanide (2.5 mg) compared with placebo and to bumetanide (250 micrograms). There were no differences between the latter two treatments. Angiotensin II was increased significantly 30 min after frusemide 100 mg and bumetanide 2.5 mg, and by all four treatments at 50 min when compared with placebo. There were no significant differences between either of the low doses or the higher doses. Plasma noradrenaline was unchanged by all treatments. 4. Frusemide 100 mg and bumetanide 2.5 mg have the same effect...Continue Reading


Mar 1, 1978·British Journal of Clinical Pharmacology·L E RamsayP Scott
Sep 1, 1976·Circulation Research·J C FrölichJ A Oates
Feb 1, 1977·Clinical Science and Molecular Medicine·J L ImbsJ Schwartz
Apr 1, 1977·British Journal of Clinical Pharmacology·R A BranchD Levine
Jan 1, 1977·Acta Medica Scandinavica·A M Abrahamsen
Apr 1, 1986·British Journal of Clinical Pharmacology·G D JohnstonM B Finch
Apr 1, 1985·British Journal of Clinical Pharmacology·G D JohnstonM B Finch
Feb 14, 1970·Lancet·B M Wright, C F Dore
May 1, 1984·British Journal of Clinical Pharmacology·I G MackayM L Watson
Nov 1, 1984·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·J NussbergerE Haber
Jan 1, 1982·The Journal of Clinical Investigation·C PatronoA Pierucci
Jul 1, 1953·The Journal of Physiology·R J WHITNEY
May 1, 1945·The Journal of Clinical Investigation·H W SmithM Graber

❮ Previous
Next ❯


Apr 13, 2001·Journal of the American College of Cardiology·P S JhundJ J McMurray
Dec 15, 2000·Progress in Pediatric Cardiology·L Lowrie
Apr 1, 1994·British Journal of Clinical Pharmacology·J G Motwani, A D Struthers
May 18, 1999·Pharmacology & Toxicology·J S Petersen
Jan 1, 1993·American Journal of Obstetrics and Gynecology·T F KellyR A Brace
Aug 18, 2004·International Journal of Cardiology·Lip-Bun TanDiane Barker
Oct 1, 1996·Clinical Pharmacology and Therapeutics·J E SullivanJ L Blumer
Oct 12, 2000·Journal of Cardiovascular Pharmacology·W BöckerH Schunkert
May 31, 2001·Clinical and Experimental Pharmacology & Physiology·B V MühlenL Lind

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Epigenetics Insights from Twin Studies

Find the latest research on epigenetics and twin studies here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.